Endocyte

This page shows the latest Endocyte news and features for those working in and with pharma, biotech and healthcare.

Novartis: pipeline will generate 60 filings in three years

Endocyte adding .

Latest news

Novartis culls pipeline to focus on most transformative science

$8.7bn, and cancer specialist Endocyte for $2.1bn.
Novartis buys cancer specialist Endocyte for $2.1bn

Heading up Endocyte’s pipeline is. 177. Lu-PSMA-617, a potential first-in-class drug for the treatment of metastatic castration-resistant prostate cancer (CRPC). ... Novartis said radiopharma is a “key growth driver” for its business and that
Merck's vintafolide fails ovarian cancer trial

If vintafolide is dropped, Endocyte will have to refocus its efforts on EC1456, a cancer drug for folate receptor-positive cancers in phase I testing. ... Shares in Endocyte are currently hovering above $6.50, having traded as high as $33.70 in the last
EMA backs Janssen rare disease drug for approval

it. Staying in the orphan disease area the CHMP also gave the nod to Endocyte's Vynfinit (vintafolide), a treatment for platinum-resistant ovarian cancer, along with two companion diagnostic drugs
Boehringer/Lilly's empagliflozin among CHMP recommendations

There were also recommendations for four orphan drugs: Janssen-Cilag's Sylvant (situximab) and, along with the companion diagnostic drugs Folcepri (etarfolatide) and Neocepri (folic acid), Endocyte's Vynfinit (vintafolide).

More from news
Approximately 3 fully matching, plus 7 partially matching documents found.

Latest Intelligence

Deal Watch October 2018

Novartis. Deal Type. Deal with. Details. Value. Acquisition. Endocyte. Portfolio of products and technology for. ... Endocyte’s adaptor controlled CAR‐T technology delivers the molecule FITC to the tumour through a tumour‐targeted ligand.
Charting a course for expansion

and eastern Europe - and US biotech Endocyte.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Endocyte appoints Parexel's Scot Harper to oversee clinical trials

He also previously served at Novartis and Lilly. Endocyte has appointed Dr Scot Harper as VP, clinical operations, where he will be responsible for clinical trial operations at the US biopharma ... In addition, Endocyte says it has three new drug
Endocyte brings in senior figures from BMS and Amgen

The appointments come at a crucial time for Endocyte as it prepares for the approval and launch of cancer drugs vintafolide (in partnership with Merck &Co) and etarfolatide. ... The two additions follow the hire in July 2012 of Endocyte's first chief

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Associate Director: £75, 000-90, 000

Senior Account Director development role to Business Director, H...: Excellent package

Account Director, Healthcare Marketing Agency: Salary TBC

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Senior Medical Writer: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Account Manager / Account Director: Competative

Account Director – Health Policy – Global Agency: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Medical Writer: Salary TBC

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Client Services Director – Medical Education Agency – North West...: Salary TBC

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Account Director, Medical Education: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Account Director – Healthcare Marketing – Berks: Salary TBC

Global Business Development Director – Health Education: excellent commission

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

NHS regional footprints: What to expect from 2019...
Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up: As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...